CC
AKRO

Corton Capital’s Akero Therapeutics AKRO Stock Holding History

Corton Capital’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,571
Closed -$217K – 379
2024
Q3 		$217K Buy
+7,571
New +$197K 0.11% 338
2024
Q1 		– Sell
-9,136
Closed -$213K – 500
2023
Q4 		$213K Buy
+9,136
New +$180K 0.07% 444

Other funds holding AKRO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Corton Capital's AKRO Position: Q4 2024 in Review

Corton Capital sold out of Akero Therapeutics (AKRO) in Q4 2024, closing a stake of 7,571 shares — an estimated $217K sold.

Corton Capital first reported a position in AKRO in Q4 2023 and held it in 2 quarters. The position peaked at $217K in Q3 2024. 191 funds tracked by Wall St. Rank hold AKRO as of Q4 2024.

  • Corton Capital reported no remaining Akero Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Corton Capital sold 7,571 Akero Therapeutics shares in Q4 2024, an estimated $217K.
  • Corton Capital first reported a position in Akero Therapeutics in Q4 2023 and held it in 2 quarters.
  • Corton Capital's Akero Therapeutics position peaked at $217K in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.